Logo image of UROY

URANIUM ROYALTY CORP (UROY) Stock Fundamental Analysis

USA - NASDAQ:UROY - CA91702V1013 - Common Stock

3.14 USD
-0.08 (-2.48%)
Last: 9/12/2025, 8:22:49 PM
3.16 USD
+0.02 (+0.64%)
After Hours: 9/12/2025, 8:22:49 PM
Fundamental Rating

2

UROY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 210 industry peers in the Oil, Gas & Consumable Fuels industry. UROY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UROY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

UROY had negative earnings in the past year.
UROY had a negative operating cash flow in the past year.
UROY had negative earnings in 4 of the past 5 years.
UROY had a negative operating cash flow in each of the past 5 years.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

UROY has a worse Return On Assets (-1.91%) than 71.43% of its industry peers.
The Return On Equity of UROY (-1.92%) is worse than 68.57% of its industry peers.
Industry RankSector Rank
ROA -1.91%
ROE -1.92%
ROIC N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

The Gross Margin of UROY (22.68%) is worse than 65.24% of its industry peers.
The Profit Margin and Operating Margin are not available for UROY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

More info and screens

6

2. Health

2.1 Basic Checks

UROY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for UROY has been increased compared to 1 year ago.
The number of shares outstanding for UROY has been increased compared to 5 years ago.
UROY has a worse debt/assets ratio than last year.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 297.29 indicates that UROY is not in any danger for bankruptcy at the moment.
UROY has a Altman-Z score of 297.29. This is amongst the best in the industry. UROY outperforms 99.52% of its industry peers.
UROY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
UROY has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. UROY outperforms 84.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 297.29
ROIC/WACCN/A
WACC8.2%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

UROY has a Current Ratio of 233.49. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 233.49, UROY belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 20.25 indicates that UROY has no problem at all paying its short term obligations.
UROY has a better Quick ratio (20.25) than 98.10% of its industry peers.
Industry RankSector Rank
Current Ratio 233.49
Quick Ratio 20.25
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for UROY have decreased strongly by -154.13% in the last year.
UROY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.48%.
EPS 1Y (TTM)-154.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-63.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.31%

3.2 Future

UROY is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -147.03% yearly.
The Revenue is expected to decrease by -37.84% on average over the next years. This is quite bad
EPS Next Y1301.2%
EPS Next 2Y-246.58%
EPS Next 3Y-147.03%
EPS Next 5YN/A
Revenue Next Year204.41%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UROY. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 107.63, UROY can be considered very expensive at the moment.
UROY's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. UROY is more expensive than 67.14% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, UROY is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 107.63
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UROY's earnings are expected to decrease with -147.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-246.58%
EPS Next 3Y-147.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UROY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

URANIUM ROYALTY CORP

NASDAQ:UROY (9/12/2025, 8:22:49 PM)

After market: 3.16 +0.02 (+0.64%)

3.14

-0.08 (-2.48%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)09-10 2025-09-10
Earnings (Next)12-10 2025-12-10
Inst Owners27.67%
Inst Owner Change17.74%
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap419.63M
Analysts77.5
Price Target3.42 (8.92%)
Short Float %9.24%
Short Ratio3.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.5%
Min EPS beat(2)0.99%
Max EPS beat(2)100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-82.27%
Min Revenue beat(2)-99.97%
Max Revenue beat(2)-64.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.84%
PT rev (3m)-0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)339.95%
EPS NY rev (3m)339.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)44.84%
Revenue NY rev (3m)210.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 107.63
P/S 37.26
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0.03
Fwd EY0.93%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.08
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.91%
ROE -1.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.68%
FCFM N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9653.33%
Cap/Sales 74.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 233.49
Quick Ratio 20.25
Altman-Z 297.29
F-Score2
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-154.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y1301.2%
EPS Next 2Y-246.58%
EPS Next 3Y-147.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.31%
Revenue Next Year204.41%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A
EBIT growth 1Y-167.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.09%
EBIT Next 3Y3.44%
EBIT Next 5YN/A
FCF growth 1Y68.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.37%
OCF growth 3YN/A
OCF growth 5YN/A